Updates to the 2024 CSCO advanced non-small cell lung cancer guidelines  

作　　者：Jiale Wang Tianyu Qiu Shengxiang Ren 

机构地区：[1]School of Medicine,Tongji University,Shanghai 200331,China [2]Department of Medical Oncology,Shanghai Pulmonary Hospital,School of Medicine,Tongji University,Shanghai 200433,China

出　　处：《Cancer Biology & Medicine》2025年第2期77-82,共6页癌症生物学与医学(英文版)

基　　金：supported by the Shanghai Excellent Academic Leader(Grant No.21XD1423200)。

摘　　要：In the past year,several advancements have been achieved in the treatment of advanced non-small cell lung cancer(NSCLC),particularly in the areas of immunotherapy and targeted therapy.These achievements have provided additional options for improving patient outcomes.The 2024 Chinese Society of Clinical Oncology Guidelines for NSCLC(CSCO NSCLC),a key reference for clinical oncologists in China,have incorporated current global research and adapted recommendations for applicability in real-world scenarios in China.This update covers not only patient selection,efficacy,and safety,but also considers economics,and accessibility,with an aim to provide more precise and comprehensive treatment guidance for Chinese oncologists.

关 键 词：csco guidelines targeted therapythese advanced non small cell lung cancer clinical oncologists IMMUNOTHERAPY ACCESSIBILITY economic considerations targeted therapy 

分 类 号：R734.2[医药卫生—肿瘤]